Literature DB >> 32529300

Glucose transport in lymphocytes.

Florian Lang1,2, Yogesh Singh3, Madhuri S Salker4, Ke Ma5, Aleksandra A Pandyra6,7, Philipp A Lang6, Karl S Lang8.   

Abstract

Glucose uptake into lymphocytes is accomplished by non-concentrative glucose carriers of the GLUT family (GLUT1, GLUT3, GLUT4, GLUT6) and/or by the Na+-coupled glucose carrier SGLT1. The latter accumulates glucose against glucose gradients and is still effective at very low extracellular glucose concentrations. Signaling involved in SGLT1 expression and activity includes protein kinase A (PKA), protein kinase C (PKC), serum- and glucocorticoid-inducible kinase (SGK1), AMP-activated kinase (AMPK), and Janus kinases (JAK2 and JAK3). Glucose taken up is partially stored as glycogen. In hypoxic environments, such as in tumors as well as infected and inflamed tissues, lymphocytes depend on energy production from glycogen-dependent glycolysis. The lack of SGLT1 may compromise glycogen storage and thus lymphocyte survival and function in hypoxic tissues. Accordingly, in mice, genetic knockout of sglt1 compromised bacterial clearance following Listeria monocytogenes infection leading to an invariably lethal course of the disease. Whether the effect was due to the lack of sglt1 in lymphocytes or in other cell types still remains to be determined. Clearly, additional experimental effort is required to define the role of glucose transport by GLUTs and particularly by SGLT1 for lymphocyte survival and function, as well as orchestration of the host defense against tumors and bacterial infections.

Entities:  

Keywords:  Bacterial infection; Cancer; Cytotoxic T lymphocytes; Energy depletion; GLUT; Janus kinases; Jurkat T cells; SGLT1

Mesh:

Substances:

Year:  2020        PMID: 32529300     DOI: 10.1007/s00424-020-02416-y

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  7 in total

1.  Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling.

Authors:  Sara Svensson Akusjärvi; Anoop T Ambikan; Shuba Krishnan; Soham Gupta; Maike Sperk; Ákos Végvári; Flora Mikaeloff; Katie Healy; Jan Vesterbacka; Piotr Nowak; Anders Sönnerborg; Ujjwal Neogi
Journal:  iScience       Date:  2021-12-10

2.  MicroRNA-mediated metabolic reprogramming of chimeric antigen receptor T cells.

Authors:  Seyed Mohammad Ali Hosseini Rad; Joshua Colin Halpin; Supannikar Tawinwung; Koramit Suppipat; Nattiya Hirankarn; Alexander D McLellan
Journal:  Immunol Cell Biol       Date:  2022-05-04       Impact factor: 5.853

3.  Dexamethasone enhances glucose uptake by SGLT1 and GLUT1 and boosts ATP generation through the PPP-TCA cycle in bovine neutrophils.

Authors:  Xinbo Wang; Mingyu Tang; Yuming Zhang; Yansong Li; Jingdong Mao; Qinghua Deng; Shusen Li; Zhenwei Jia; Liyin Du
Journal:  J Vet Sci       Date:  2022-09       Impact factor: 1.603

4.  Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways.

Authors:  Nami Lee; Yu Jung Heo; Sung-E Choi; Ja Young Jeon; Seung Jin Han; Dae Jung Kim; Yup Kang; Kwan Woo Lee; Hae Jin Kim
Journal:  J Immunol Res       Date:  2021-06-02       Impact factor: 4.818

5.  GLUT3 as an Intersection of Glycerophospholipid Metabolism and the Innate Immune Response to Candida albicans.

Authors:  Xian Wu; Ge Zhang; Wen-Hang Yang; Jing-Tao Cui; Li Zhang; Meng Xiao; Ying-Chun Xu
Journal:  Front Cell Infect Microbiol       Date:  2021-06-18       Impact factor: 5.293

6.  A special issue on glucose transporters in health and disease.

Authors:  Hermann Koepsell; Volker Vallon
Journal:  Pflugers Arch       Date:  2020-08-11       Impact factor: 4.458

7.  Dual Mechanisms of Metabolism and Gene Expression of the CCRF-CEM Leukemia Cells under Glucocorticoid Treatment.

Authors:  George I Lambrou; Theodoros Karakonstantakis; Spiros Vlahopoulos; Apostolos Zaravinos
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.